Oncology Unlocking the scalability of allogeneic CAR-T Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.
Oncology Bridging the innovation gap: Scalable cell therapies, adapti... Biotech must build manufacturing and trial models that make cell therapies scalable, accessible & commercially viable.
Market Access Why 70% of pharma partnership spend misses patients Finding a start-up or building an app is the cheap part; combining capabilities into something that scales across markets is the expensive part.
Digital Why AI sovereignty is becoming a requirement for businesses The companies that will lead in this next phase are those that treat AI as an integrated part of their operational architecture.
Digital AI, trust, and transformation: What the NHS needs for safe a... As AI becomes more embedded within national health system priorities, the need for clear and responsible guardrails has become increasingly critical.
R&D From in silico to in vivo: Why development strategy now dete... As discovery becomes faster and more accessible, the differentiator shifts downstream.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
